Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapies: Expanding the use of PARP inhibitors.

Literature DB >> 28642599

Targeted therapies: Expanding the use of PARP inhibitors.

Sarah Seton-Rogers.

Abstract

Entities: Gene

Year: 2017 PMID： 28642599 DOI： 10.1038/nrc.2017.50

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

× No keyword cloud information.

2 in total

1. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Authors: Likun Li; Styliani Karanika; Guang Yang; Jiangxiang Wang; Sanghee Park; Bradley M Broom; Ganiraju C Manyam; Wenhui Wu; Yong Luo; Spyridon Basourakos; Jian H Song; Gary E Gallick; Theodoros Karantanos; Dimitrios Korentzelos; Abul Kalam Azad; Jeri Kim; Paul G Corn; Ana M Aparicio; Christopher J Logothetis; Patricia Troncoso; Timothy Heffernan; Carlo Toniatti; Hyun-Sung Lee; Ju-Seog Lee; Xuemei Zuo; Wenjun Chang; Jianhua Yin; Timothy C Thompson
Journal: Sci Signal Date: 2017-05-23 Impact factor: 8.192

2. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors: Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal: Sci Transl Med Date: 2017-05-31 Impact factor: 17.956

2 in total

4 in total

1. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.

Authors: Xi Zhang; Peng Huang; Liqiong Wang; Shu Chen; Basappa Basappa; Tao Zhu; Peter E Lobie; Vijay Pandey
Journal: Cell Death Dis Date: 2022-06-20 Impact factor: 9.685

Targeted therapies: Expanding the use of PARP inhibitors.

1. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

2. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

1. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.

2. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Review 3. Type 2 Diabetes: Multiple Genes, Multiple Diseases.

4. m⁵C modification of mRNA serves a DNA damage code to promote homologous recombination.

Targeted therapies: Expanding the use of PARP inhibitors.

1. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

2. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

1. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.

2. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Review 3. Type 2 Diabetes: Multiple Genes, Multiple Diseases.

4. m5C modification of mRNA serves a DNA damage code to promote homologous recombination.

4. m⁵C modification of mRNA serves a DNA damage code to promote homologous recombination.